BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 and Item 9.01 of this Form 8-K is being furnished and
shall not be deemed filed for the purpose of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section. The information in Item 2.02
and Item 9.01 of this Form 8-K shall not be incorporated by
reference into any registration statement or other document to
the Securities Act of 1933, as amended.
| Item 2.02. | Results of Operations and Financial Condition. |
On February 14, 2017, Bioanalytical Systems, Inc. issued a press
release announcing results for the first three months of fiscal
2017 ended December 31, 2016. The full text of the press release
is furnished as Exhibit 99.1 to this Form 8-K and is incorporated
herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
| (a) | Not applicable. |
| (b) | Not applicable. |
| (c) | Not applicable. |
| (d) | Exhibits |
| 99.1 |
Bioanalytical Systems, Inc. press release, issued February 14, 2017. |
About BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI)
Bioanalytical Systems, Inc. (BASi) is a contract research organization (CRO) providing drug discovery and development services and analytical instruments. The Company operates through two segments: contract research services and research products. Its contract research services segment provides research and development support on a contract basis directly to pharmaceutical companies. Its research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers and medical research institutions. Its Culex family of robotic automated dose delivery, blood and other biofluids sampling and physiological parameters measurement systems enable researchers to determine pharmacokinetic/pharmacodynamic (PK/PD) profiles of drugs in large and small animal models. The Company’s bioanalytical services group supports research, preclinical and clinical programs. BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) Recent Trading Information
BIOANALYTICAL SYSTEMS, INC. (NASDAQ:BASI) closed its last trading session up +0.36 at 1.27 with 743,109 shares trading hands.
